Bin selber noch am Überlegen, ob ich hier reingehen soll:
Integra Lifesciences Holdings Corp. (IART)
September 01, 2000 08:45
Integra LifeSciences Named One of New Jersey's Fastest Growing Technology Companies in
Deloitte & Touche's 'Fast 50' Program
PLAINSBORO, N.J.--(BUSINESS WIRE)--Sept. 1, 2000--Integra LifeSciences Holdings Corporation (Nasdaq: IART) has been named to Deloitte &
Touche's prestigious "Fast 50" program for New Jersey, a ranking of the 50 fastest growing technology companies in the area.
An increase in revenues of 315% over the five year period of 1995 through 1999 ranked Integra 34th overall in the Fast 50 for New Jersey.
Rankings for the Fast 50 are based on the percentage of growth in revenues from 1995 through 1999.
"I am delighted with the recognition that comes with being named to the New Jersey Fast 50," Stuart Essig, President and Chief Executive Officer
of Integra said. "Integra has transformed itself over the past five years from a company engaged primarily in the development of tissue regeneration
products to a diversified medical technology company with a stable revenue base of commercially successful products. The Company's
tremendous growth in revenues has been fueled by strategic acquisitions and new product launches, and operating results have improved
dramatically with this growth. Just recently, Integra reported its first quarterly operating profit before amortization charges, which is very gratifying
and shows that we have reached a new level in our business."
"To attain a listing on the Fast 50 is no easy feat, and we at Deloitte & Touche congratulate Integra for attaining this honor," said Richard
Kabobjian, Managing Partner, Assurance and Advisory Services.
Winners of the 21 regional Fast 50 Programs in the United States are automatically entered in the Deloitte & Touche Technology Fast 500
Program, which ranks the U.S. and Canada's top 500 fastest-growing technology companies. For more information on the Deloitte & Touche Fast
50 or Fast 500 programs, visit the website at www.fast.500.com.
Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials. The Company's
operations consist of Integra NeuroSciences, which is a leading provider of implants, instruments, and monitors used in neurosurgery,
neurotrauma, and related critical care, and Integra LifeSciences, which develops and manufactures a variety of medical products and devices,
including products based on the Company's proprietary tissue regeneration technology. Integra NeuroSciences sells its products primarily through
a direct sales organization, and Integra LifeSciences sells primarily through strategic alliances and distributors. Manufacturing and research
facilities are located in Plainsboro, NJ, San Diego, CA, Anasco, Puerto Rico, Andover, England and Exton, PA. The Company has approximately
485 permanent employees. Please visit the Company's website at (www.integra-LS.com).
Integra Lifesciences Holdings Corp. (IART)
September 01, 2000 08:45
Integra LifeSciences Named One of New Jersey's Fastest Growing Technology Companies in
Deloitte & Touche's 'Fast 50' Program
PLAINSBORO, N.J.--(BUSINESS WIRE)--Sept. 1, 2000--Integra LifeSciences Holdings Corporation (Nasdaq: IART) has been named to Deloitte &
Touche's prestigious "Fast 50" program for New Jersey, a ranking of the 50 fastest growing technology companies in the area.
An increase in revenues of 315% over the five year period of 1995 through 1999 ranked Integra 34th overall in the Fast 50 for New Jersey.
Rankings for the Fast 50 are based on the percentage of growth in revenues from 1995 through 1999.
"I am delighted with the recognition that comes with being named to the New Jersey Fast 50," Stuart Essig, President and Chief Executive Officer
of Integra said. "Integra has transformed itself over the past five years from a company engaged primarily in the development of tissue regeneration
products to a diversified medical technology company with a stable revenue base of commercially successful products. The Company's
tremendous growth in revenues has been fueled by strategic acquisitions and new product launches, and operating results have improved
dramatically with this growth. Just recently, Integra reported its first quarterly operating profit before amortization charges, which is very gratifying
and shows that we have reached a new level in our business."
"To attain a listing on the Fast 50 is no easy feat, and we at Deloitte & Touche congratulate Integra for attaining this honor," said Richard
Kabobjian, Managing Partner, Assurance and Advisory Services.
Winners of the 21 regional Fast 50 Programs in the United States are automatically entered in the Deloitte & Touche Technology Fast 500
Program, which ranks the U.S. and Canada's top 500 fastest-growing technology companies. For more information on the Deloitte & Touche Fast
50 or Fast 500 programs, visit the website at www.fast.500.com.
Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials. The Company's
operations consist of Integra NeuroSciences, which is a leading provider of implants, instruments, and monitors used in neurosurgery,
neurotrauma, and related critical care, and Integra LifeSciences, which develops and manufactures a variety of medical products and devices,
including products based on the Company's proprietary tissue regeneration technology. Integra NeuroSciences sells its products primarily through
a direct sales organization, and Integra LifeSciences sells primarily through strategic alliances and distributors. Manufacturing and research
facilities are located in Plainsboro, NJ, San Diego, CA, Anasco, Puerto Rico, Andover, England and Exton, PA. The Company has approximately
485 permanent employees. Please visit the Company's website at (www.integra-LS.com).
